Tirzepatide before and after claims: what the trials actually show

Last updated 2026-07-27

What are 'before and after' claims for tirzepatide, and why are they unreliable on their own?

A before-and-after claim is a pair of photos or a testimonial saying someone lost weight on tirzepatide, usually posted with a timeline like "12 weeks" or "6 months." They're everywhere on Instagram, TikTok, and med spa websites. The problem isn't that the weight loss is fake. It's that the photo tells you nothing about dose, duration, starting weight, concurrent diet changes, exercise, whether the product was FDA-approved Zepbound/Mounjaro or a compounded version, or whether the person is even representative of anything. A single photo pair is an anecdote with an n of 1. It can't tell you the average result, the variance, or the side effects the person didn't post about. That's exactly why the FDA runs randomized controlled trials before approving a drug, and why this article leans on those trial numbers instead of testimonials. This doesn't mean before-and-after posts are lying. Plenty of them reflect real outcomes. It just means they're not evidence in the scientific sense, and they shouldn't be the thing that decides whether tirzepatide is right for you. The trial data below is.

What weight loss did tirzepatide actually produce in clinical trials?

In SURMOUNT-1, the trial that got tirzepatide approved for adults with obesity or overweight (without diabetes), participants on the 15mg dose lost an average of 22.5% of body weight at 72 weeks, compared with 2.4% in the placebo group ^[1]. The 5mg dose group averaged 15.0% loss and the 10mg group averaged 19.5% loss over the same period ^[1]. These are trial averages, not guarantees. The published results reported that at week 72, 96.3% of participants on the highest dose lost at least 5% of body weight, and more than half lost 20% or more ^[1]. That's a wide range hiding inside that headline average, exactly the kind of nuance a before-and-after photo can't show. SURMOUNT-1 enrolled 2,539 adults and ran for 72 weeks total, with a 20-week dose escalation period before participants reached their target maintenance dose ^[1]. That escalation matters: nobody starts at 15mg. The Tirz Rx dosage guide covers how that titration schedule works in practice. SURMOUNT-2, which enrolled adults with type 2 diabetes and obesity, showed smaller but still substantial losses: 12.8% at the 10mg dose and 14.7% at the 15mg dose over 72 weeks, versus 3.2% for placebo ^[2]. Diabetes tends to blunt weight loss response somewhat compared to SURMOUNT-1's non-diabetic population, which is a real and clinically important difference worth knowing before comparing your results to someone else's photos.

What does tirzepatide do for A1C and blood sugar in type 2 diabetes?

The SURPASS trial program is what got tirzepatide (as Mounjaro) approved for type 2 diabetes in May 2022 ^[3]. Across the SURPASS-1 through SURPASS-5 trials, tirzepatide reduced A1C by roughly 1.8 to 2.1 percentage points depending on dose and comparator ^[4]. In SURPASS-2, tirzepatide at the 15mg dose reduced A1C by 2.30 percentage points at 40 weeks, compared with 1.86 points for semaglutide 1mg, a head-to-head comparison against another GLP-1 drug rather than placebo ^[4]. The study's authors concluded that "tirzepatide at all doses was noninferior and superior to semaglutide at a dose of 1 mg with respect to the change in the glycated hemoglobin level from baseline" ^[4]. Mounjaro carries FDA approval specifically for glycemic control in type 2 diabetes; Zepbound carries a separate FDA approval for chronic weight management. Same molecule, same manufacturer (Eli Lilly), different approved indications and different trial programs backing each one ^[3][5]. If you see a before-and-after post, it's worth asking which condition the person was actually treating, because the expected numbers differ.

How fast does weight loss actually happen? What does the trial timeline look like?

Trial data shows a gradual curve, not a cliff. In SURMOUNT-1, meaningful separation from placebo appeared within the first 4 to 8 weeks, but the bulk of total weight loss accrued over months, not weeks ^[1]. Dosing itself is staged over 20 weeks: participants started at 2.5mg weekly for 4 weeks (a non-therapeutic starting dose meant to reduce GI side effects), then increased in 2.5mg increments roughly every 4 weeks up to their target dose ^[1]. That means someone on a 15mg target dose doesn't actually reach 15mg until around week 20, and their most dramatic before-and-after comparisons are typically drawn from week 20 to week 72, the maintenance period. Anyone posting a "before and after" at 4 or 6 weeks is showing you the titration phase, not the drug's full effect. For a realistic sense of how the schedule unfolds week to week, the Tirz Rx dosage calculator walks through typical escalation timing, and Tirz Rx cycle length covers how long people typically stay on treatment to reach and hold a target weight.

What happens to weight after stopping tirzepatide?

Weight tends to come back, at least partially, once the drug is stopped. This is documented in the SURMOUNT-4 trial design, which included a withdrawal phase specifically to study this question: participants who reached maintenance dose were randomized to either continue tirzepatide or switch to placebo for an additional 52 weeks ^[6]. Those switched to placebo regained a substantial portion of the weight they'd lost, while those who continued tirzepatide continued to lose or maintain ^[6]. This mirrors what's been shown with other GLP-1 drugs like semaglutide, where discontinuation studies found most of the lost weight returns within a year. The practical takeaway: tirzepatide functions more like a chronic maintenance therapy for a chronic condition than a short course that "fixes" weight permanently. Anyone showing a before-and-after without mentioning what happens after the photo was taken, and whether they're still on the drug, is giving you an incomplete picture.

Does compounded tirzepatide produce the same before-and-after results as brand-name Zepbound or Mounjaro?

Nobody knows for certain, and that's the honest answer. Compounded tirzepatide isn't FDA-approved as a product. It's produced by compounding pharmacies, typically during periods when the FDA listed brand-name tirzepatide as being in shortage, under a legal framework that allows compounding when a commercially available drug is unavailable ^[7]. The active ingredient, tirzepatide peptide, is chemically the same molecule whether it's in a name-brand pen or a compounded vial, assuming the compounding pharmacy sourced pure, correctly identified active pharmaceutical ingredient and reconstituted it properly. But there's no large randomized trial testing compounded tirzepatide specifically. The SURMOUNT and SURPASS numbers above were generated using the manufacturer's branded product, run through FDA's approval process with controlled manufacturing ^[1][3]. The FDA has published warnings about compounded semaglutide and tirzepatide products found to contain incorrect salt forms, impurities, or dosing errors ^[8]. That doesn't mean every compounded product is unsafe, but it does mean the before-and-after result you see from someone using a compounded product carries more sourcing uncertainty than one from someone on branded Zepbound. If you're going the compounded route, working with a provider who reviews dosing and a pharmacy with a verifiable track record matters more here than it would with an FDA-approved product. This is one area where Tirz Rx positions itself as a provider-reviewed pathway that connects patients to a fulfilling pharmacy partner, rather than manufacturing or compounding anything itself.

What side effects show up in the trials that before-and-after photos never mention?

Gastrointestinal side effects are the most common reason people stop, or the thing people quietly don't post about. In SURMOUNT-1, nausea occurred in roughly 24-33% of participants depending on dose, diarrhea in about 15-17%, vomiting in about 10-13%, and constipation in about 11-17% ^[1]. Most were described as mild to moderate and concentrated during dose escalation. Discontinuation due to adverse events occurred in about 4.3% to 7.1% of tirzepatide-treated participants across doses, versus 2.6% on placebo ^[1]. That's not nothing. A meaningful minority of people don't tolerate the drug well enough to reach their target dose or stay on it long term. Beyond GI symptoms, tirzepatide's prescribing information carries a boxed warning for risk of thyroid C-cell tumors, based on findings in rodent studies; it's contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[9]. The label also lists warnings for acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), acute kidney injury (often secondary to GI-related dehydration), hypoglycemia when combined with insulin or sulfonylureas, and severe gastrointestinal disease ^[9]. None of that shows up in a flattering side-by-side photo. It's worth reading the actual label, more than the results, before starting.

How does tirzepatide's before-and-after data compare to semaglutide (Wegovy/Ozempic)?

The most direct comparison comes from SURMOUNT-2 and separately from the head-to-head SURPASS-2 diabetes trial, plus a large real-world retrospective study. In the diabetes head-to-head, tirzepatide beat semaglutide 1mg on A1C reduction (2.30 vs 1.86 percentage points at 40 weeks) ^[4]. For weight specifically, a retrospective cohort study published in JAMA Internal Medicine, using electronic health record data from over 18,000 patients, found tirzepatide users were more likely to achieve 10%, 15%, and 20% weight loss thresholds at 12 months than semaglutide users ^[10]. This wasn't a randomized trial, so it carries the usual limitations of retrospective data (channeling bias, unmeasured confounders), but it's the largest comparative dataset available outside of industry trials designed around a single drug. | Trial | Drug | Population | Duration | Average weight loss / A1C change |

Why do some people lose much more or much less weight than the trial average?

Trial averages hide real variation. In SURMOUNT-1's 15mg group, the range spanned from people who lost minimal weight to those who lost well over 20% ^[1]. Factors that plausibly explain differences include starting BMI, adherence to the full titration schedule, concurrent diet and activity changes (SURMOUNT-1 included lifestyle intervention as a co-intervention, not tirzepatide alone) ^[1], GI tolerability (people who can't tolerate higher doses often plateau at a lower, less effective dose), and individual metabolic and genetic factors that aren't fully understood yet. This is why a stranger's before-and-after photo, even a genuine one, isn't a reliable predictor of your own outcome. It's one data point from one person's unique combination of dose, diet, genetics, and consistency. The trial average of 22.5% is a population statistic; your result could land well above or below it, and there's no reliable way to know in advance which side of the curve you'll fall on. Proper injection technique and dose consistency do matter for getting anywhere close to trial-comparable results. Missed doses, incorrect reconstitution of compounded product, or inconsistent injection sites can all reduce effective absorption. The Tirz Rx how to inject and Tirz Rx injection sites guides cover the technique side of that, and how to reconstitute Tirz Rx covers the compounded-vial-specific steps that don't apply to pre-filled pens.

Who should not use tirzepatide, regardless of what a before-and-after shows?

Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, per the FDA-approved prescribing information's boxed warning ^[9]. It's also contraindicated in people with a known serious hypersensitivity to tirzepatide or any of its components ^[9]. It should be used with caution, and under close medical supervision, in people with a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), diabetic retinopathy (particularly when combined with insulin, per findings in related GLP-1 trials), or a history of gallbladder disease ^[9]. It is not approved for use in type 1 diabetes or for treating diabetic ketoacidosis ^[9]. Pregnancy and breastfeeding are additional contraindications the label addresses separately; animal studies showed adverse effects on fetal development, and the drug hasn't been studied in pregnant humans ^[9]. None of these contraindications show up in a photo. A provider who actually reviews your history before prescribing is doing something a testimonial can't.

How should I evaluate a tirzepatide before-and-after claim I see online?

Ask what dose and how long. A photo captioned "6 months" without a dose number is missing the single most predictive variable in the trial data. Someone at 15mg for 72 weeks and someone at 5mg for 12 weeks aren't comparable, and SURMOUNT-1 shows why: the gap between the 5mg and 15mg average results was roughly 7.5 percentage points of body weight ^[1]. Ask whether it was branded product or compounded, and if compounded, from where. Ask whether diet and exercise changed alongside the medication, since every major tirzepatide trial paired the drug with a lifestyle intervention, not drug alone ^[1][2]. Ask what side effects they had and whether they mention any, since selective posting is the norm on social media. And treat any single photo as exactly what it is: one uncontrolled data point. The number that actually generalizes is the trial average, with its reported range, from a peer-reviewed, FDA-reviewed study. That's the number to plan around, not someone's Instagram caption.

Frequently asked questions

How much weight can I realistically expect to lose on tirzepatide?

SURMOUNT-1 found average losses of 15.0% at 5mg, 19.5% at 10mg, and 22.5% at 15mg over 72 weeks, versus 2.4% on placebo, in adults with obesity but no diabetes ^[1]. People with type 2 diabetes tend to lose somewhat less, per SURMOUNT-2 (12.8-14.7%) ^[2]. Individual results vary widely around these averages.

Are before-and-after photos of tirzepatide accurate or exaggerated?

Many are accurate reflections of what happened to that one person, but they can't be verified for dose, timeline, diet changes, or product authenticity. They're anecdotes, not data. The reliable numbers come from randomized, peer-reviewed trials like SURMOUNT-1 and SURMOUNT-2, which report averages and ranges across thousands of participants ^[1][2].

How long does it take to see results on tirzepatide?

Trial data shows measurable separation from placebo within 4-8 weeks, but most weight loss accrues over the full 20-week dose titration plus subsequent maintenance months. SURMOUNT-1's headline 22.5% average loss was measured at 72 weeks, not at any earlier point ^[1].

Does tirzepatide work differently for diabetes versus weight loss?

It's FDA-approved under two brand names for two indications: Mounjaro for type 2 diabetes glycemic control, backed by the SURPASS trials, and Zepbound for chronic weight management, backed by SURMOUNT ^[3][5]. The molecule is identical; the approved use, trial population, and typical outcome reported differ.

What happens to weight after stopping tirzepatide?

Weight tends to come back, at least partially. SURMOUNT-4's withdrawal phase showed that participants switched to placebo after reaching maintenance dose regained a substantial portion of lost weight, while those who continued tirzepatide kept losing or maintained ^[6]. It behaves as a chronic therapy, not a one-time fix.

Is compounded tirzepatide as effective as brand-name Zepbound or Mounjaro?

There's no large randomized trial testing compounded tirzepatide specifically, so nobody can say with trial-level certainty. The active molecule should be pharmacologically identical if properly sourced and compounded, but the FDA has flagged quality issues in some compounded GLP-1/GIP products, including incorrect salt forms and dosing errors ^[8].

What are the most common tirzepatide side effects?

Nausea (24-33%), diarrhea (15-17%), vomiting (10-13%), and constipation (11-17%) were the most common in SURMOUNT-1, concentrated mostly during dose escalation ^[1]. About 4.3-7.1% of participants discontinued due to adverse events, versus 2.6% on placebo ^[1].

Who should not take tirzepatide?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take it; this is a boxed warning on the FDA label ^[9]. Caution and close supervision are needed for people with prior pancreatitis, severe GI disease, or gallbladder disease. It's not studied for use in pregnancy.

How does tirzepatide compare to semaglutide for weight loss?

A retrospective study of over 18,000 patients found tirzepatide users more often reached 10%, 15%, and 20% weight loss thresholds at 12 months than semaglutide users ^[10]. In a head-to-head diabetes trial, tirzepatide also outperformed semaglutide 1mg on A1C (2.30 vs 1.86 point reduction) ^[4]. Neither comparison is a guarantee for any individual.

Why did my weight loss look different from someone else's before-and-after?

Trial averages hide wide individual variation driven by starting BMI, dose reached, adherence, diet and activity changes, and GI tolerability. SURMOUNT-1 paired tirzepatide with lifestyle intervention in every arm, not drug alone, so diet and exercise consistency likely explains part of the spread between people ^[1].

Does diet and exercise matter if I'm on tirzepatide?

Yes. Every major trial, including SURMOUNT-1 and SURMOUNT-2, delivered tirzepatide alongside a reduced-calorie diet and increased physical activity counseling as the study protocol, not as an optional add-on ^[1][2]. The published results reflect drug plus lifestyle intervention together, not medication in isolation.

How is tirzepatide dosed during a typical treatment course?

Trial protocol started at 2.5mg weekly for 4 weeks (a non-therapeutic starting dose), then increased by 2.5mg roughly every 4 weeks toward a target maintenance dose of 5mg, 10mg, or 15mg ^[1]. Full details on escalation timing are in the Tirz Rx dosage and dosage calculator guides.

Sources

1. Jastreboff AM, et al., New England Journal of Medicine, SURMOUNT-1: SURMOUNT-1 weight loss results, dosing schedule, and side effect rates
2. Garvey WT, et al., The Lancet, SURMOUNT-2: SURMOUNT-2 weight loss results in adults with type 2 diabetes
3. Frías JP, et al., New England Journal of Medicine, SURPASS-2: Tirzepatide vs semaglutide 1mg A1C reduction head-to-head comparison
4. FDA, Zepbound approval announcement: FDA approval of tirzepatide (Zepbound) for chronic weight management
5. NIH ClinicalTrials.gov, SURMOUNT-4 study record: SURMOUNT-4 withdrawal design comparing continued tirzepatide vs placebo after dose achievement
6. FDA, Compounding when drugs are in shortage (FD&C Act Section 503B): Legal basis allowing compounding pharmacies to produce tirzepatide during shortages
7. FDA, Medications containing semaglutide marketed for type 2 diabetes or weight loss: FDA warnings about quality and dosing issues in compounded GLP-1 products
8. FDA, Zepbound prescribing information: Boxed warning for thyroid C-cell tumors, contraindications, and warnings including pancreatitis and gallbladder disease
9. Rodriguez PJ, et al., JAMA Internal Medicine: Retrospective comparison of weight loss thresholds achieved by tirzepatide vs semaglutide users
10. Wilding JPH, et al., New England Journal of Medicine, STEP 1: Semaglutide 2.4mg average weight loss in STEP 1 trial for comparison